First Trust Advisors LP Decreases Stock Position in HealthEquity, Inc. (NASDAQ:HQY)

First Trust Advisors LP lowered its holdings in shares of HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 42.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 84,307 shares of the company's stock after selling 61,589 shares during the quarter. First Trust Advisors LP owned 0.10% of HealthEquity worth $8,089,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of HQY. Wealthfront Advisers LLC bought a new position in shares of HealthEquity in the 4th quarter valued at about $10,304,089,000. Vanguard Group Inc. lifted its stake in shares of HealthEquity by 1.1% in the 4th quarter. Vanguard Group Inc. now owns 8,976,091 shares of the company's stock valued at $861,256,000 after purchasing an additional 99,624 shares during the last quarter. FMR LLC boosted its holdings in shares of HealthEquity by 2.4% in the 4th quarter. FMR LLC now owns 5,415,800 shares of the company's stock worth $519,646,000 after purchasing an additional 125,684 shares during the period. Geode Capital Management LLC boosted its holdings in shares of HealthEquity by 0.5% in the 4th quarter. Geode Capital Management LLC now owns 2,089,398 shares of the company's stock worth $200,522,000 after purchasing an additional 10,421 shares during the period. Finally, Franklin Resources Inc. increased its position in shares of HealthEquity by 0.7% during the 3rd quarter. Franklin Resources Inc. now owns 1,640,215 shares of the company's stock valued at $139,369,000 after purchasing an additional 11,659 shares during the last quarter. Institutional investors own 99.55% of the company's stock.

Insider Buying and Selling

In other HealthEquity news, Director Robert W. Selander sold 5,750 shares of HealthEquity stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $77.65, for a total value of $446,487.50. Following the transaction, the director now owns 84,969 shares in the company, valued at $6,597,842.85. The trade was a 6.34 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael Henry Fiore sold 8,881 shares of the stock in a transaction dated Friday, April 4th. The shares were sold at an average price of $78.26, for a total transaction of $695,027.06. Following the sale, the executive vice president now directly owns 56,655 shares of the company's stock, valued at approximately $4,433,820.30. The trade was a 13.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 20,381 shares of company stock valued at $1,781,432 over the last three months. 2.20% of the stock is owned by company insiders.

HealthEquity Stock Up 3.0 %

Shares of HQY stock traded up $2.63 during mid-day trading on Friday, hitting $90.58. The stock had a trading volume of 1,475,723 shares, compared to its average volume of 781,229. HealthEquity, Inc. has a 12-month low of $65.01 and a 12-month high of $115.59. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.20 and a quick ratio of 3.20. The firm's 50-day moving average is $89.55 and its two-hundred day moving average is $96.57. The firm has a market capitalization of $7.83 billion, a P/E ratio of 83.10, a price-to-earnings-growth ratio of 1.60 and a beta of 0.45.

Wall Street Analysts Forecast Growth

Several research analysts have commented on HQY shares. Raymond James raised shares of HealthEquity from an "outperform" rating to a "strong-buy" rating and dropped their price objective for the stock from $120.00 to $115.00 in a research note on Tuesday, March 25th. KeyCorp dropped their price target on shares of HealthEquity from $110.00 to $100.00 and set an "overweight" rating for the company in a research note on Wednesday, April 16th. The Goldman Sachs Group reduced their price objective on shares of HealthEquity from $107.00 to $94.00 and set a "neutral" rating on the stock in a research report on Thursday, March 27th. Wells Fargo & Company boosted their target price on HealthEquity from $110.00 to $125.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. Finally, Barrington Research reaffirmed an "outperform" rating and set a $112.00 target price on shares of HealthEquity in a research note on Friday, April 11th. One research analyst has rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, HealthEquity has a consensus rating of "Buy" and an average target price of $111.75.

HealthEquity Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.